Sundance Biosciences Shares Positive SUN-627 Trial Data

The oral TYK2 inhibitor showed strong inhibition and central nervous system penetration in a Phase 1 clinical study.

Updated on Oct. 21, 2026 in Biotech

Isometric editorial illustration of a complex molecular structure model, representing the chemical inhibition process in scientific research. — Sundance Biosciences reported positive Phase 1 trial results for its oral TYK2 inhibitor, SUN-627, demonstrating successful central nervous system penetration. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical companies are adequately prioritizing treatments for progressive chronic diseases?

Sundance Biosciences revealed promising Phase 1 results for SUN-627, a selective oral allosteric TYK2 inhibitor, at the Joint ACTRIMS-ECTRIMS Meeting. The drug demonstrated significant target inhibition and achieved full central nervous system penetration in healthy adult volunteers.

Why it matters

The study was conducted to evaluate the safety, tolerability, and pharmacokinetics of SUN-627 to determine its potential as a therapeutic candidate. Successful CNS penetration combined with high target inhibition suggests the drug may effectively reach areas often challenging for central nervous system treatments.

The Phase 1 trial demonstrated greater than 90% inhibition of TYK2 pathway biomarkers for 24 hours with once-daily dosing. SUN-627 achieved full central nervous system penetration, with predicted steady-state exposure remaining above IC90 levels at doses of 40 mg or higher.

The players

Sundance Biosciences

A biotechnology company based in South San Francisco that focuses on the development of novel therapeutic candidates.

The details

The randomized, double-blind, placebo-controlled study utilized single-ascending and multiple-ascending dose designs to assess the drug's safety and pharmacokinetic profile. During the trial, no serious adverse events were reported, and all treatment-related adverse events were restricted to grade 1.

The 10th Joint ACTRIMS-ECTRIMS Meeting took place in Toronto from October 21-23, 2026.

The Big Picture

The presentation of data at the Joint ACTRIMS-ECTRIMS Meeting allows researchers to benchmark new neurological therapies against established industry standards. The results follow the patterns set by previous neurological advancements presented at this annual gathering.

While the trial demonstrates safety in healthy volunteers, patients must wait for further clinical trials to establish efficacy and potential treatment benefits. The lack of serious adverse events in this early stage provides a positive safety foundation for future development.

The takeaway

The successful achievement of central nervous system penetration and high TYK2 pathway inhibition supports continued development for this oral candidate. Future research will need to translate these pharmacokinetic successes into meaningful clinical outcomes for patients.